Upfront Payments In Alliances, Part Two
Continuing our analysis of upfront payments in alliances in the past year (see "Upfront Payments In Alliances, Part One", IN VIVO, Oct. 2000), we've broken out ranges in up-front payments in deals over the past year by development phase of the product or technology licensed.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."